Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files

High-throughput screening (HTS) is an effective method for lead and probe discovery that is widely used in industry and academia to identify novel chemical matter and to initiate the drug discovery process. However, HTS can be time consuming and costly and the use of subsets as an efficient alternative to screening entire compound collections has been investigated. Subsets may be selected on the basis of chemical diversity, molecular properties, biological activity diversity or biological target focus. Previously, we described a novel form of subset screening: plate-based diversity subset (PBDS) screening, in which the screening subset is constructed by plate selection (rather than individual compound cherry-picking), using algorithms that select for compound quality and chemical diversity on a plate basis. In this paper, we describe a second-generation approach to the construction of an updated subset: PBDS2, using both plate and individual compound selection, that has an improved coverage of the chemical space of the screening file, whilst only selecting the same number of plates for screening. We describe the validation of PBDS2 and its successful use in hit and lead discovery. PBDS2 screening became the default mode of singleton (one compound per well) HTS for lead discovery in Pfizer.

[1]  N. Meanwell.  Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.

[2]  E. Kwong,et al.  Advancing drug discovery: a pharmaceutics perspective. , 2015, Journal of pharmaceutical sciences.

[3]  Jürgen Bajorath,et al.  Virtual compound screening in drug discovery. , 2012, Future medicinal chemistry.

[4]  Gisbert Schneider,et al.  Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.

[5]  Fabrizio Giordanetto,et al.  Potential strategies for increasing drug-discovery productivity. , 2014, Future medicinal chemistry.

[6]  Asher Mullard,et al.  2015 FDA drug approvals , 2016, Nature Reviews Drug Discovery.

[7]  S. Planey,et al.  The influence of lipophilicity in drug discovery and design , 2012, Expert opinion on drug discovery.

[8]  Christopher W Murray,et al.  Efficient exploration of chemical space by fragment-based screening. , 2014, Progress in biophysics and molecular biology.

[9]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[10]  Valerie J. Gillet,et al.  Diversity selection algorithms , 2011 .

[11]  Highly Potent , Selective , and E ffi cacious Metabotropic Glutamate Receptor 5 ( mGluR 5 ) Negative Allosteric Modulator , 2014 .

[12]  Kevin R Clark,et al.  Small-Molecule Library Subset Screening as an Aid for Accelerating Lead Identification , 2014, Journal of biomolecular screening.

[13]  Willem P. van Hoorn,et al.  Designing Compound Subsets: Comparison of Random and Rational Approaches Using Statistical Simulation , 2007, J. Chem. Inf. Model..

[14]  Albert J. Leo,et al.  Calculating log P(oct) with no missing fragments; The problem of estimating new interaction parameters , 2000 .

[15]  Brendan Connolly,et al.  Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry. , 2008, Analytica chimica acta.

[16]  Andreas Larsson,et al.  Efficiency of hit generation and structural characterization in fragment-based ligand discovery. , 2011, Current opinion in chemical biology.

[17]  A. Harvey,et al.  The re-emergence of natural products for drug discovery in the genomics era , 2015, Nature Reviews Drug Discovery.

[18]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[19]  Eddy Arnold,et al.  Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery. , 2014, Progress in biophysics and molecular biology.

[20]  Andrew Bell,et al.  Shaping a Screening File for Maximal Lead Discovery Efficiency and Effectiveness: Elimination of Molecular Redundancy , 2012, J. Chem. Inf. Model..

[21]  Andreas Bender,et al.  Plate-Based Diversity Selection Based on Empirical HTS Data to Enhance the Number of Hits and Their Chemical Diversity , 2009, Journal of biomolecular screening.

[22]  Vinicius M Alves,et al.  Virtual screening strategies in medicinal chemistry: the state of the art and current challenges. , 2014, Current topics in medicinal chemistry.

[23]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[24]  Anne Mai Wassermann,et al.  Biodiversity of small molecules--a new perspective in screening set selection. , 2013, Drug discovery today.

[25]  D. Pereira,et al.  Origin and evolution of high throughput screening , 2007, British journal of pharmacology.

[26]  Lorenz M Mayr,et al.  Novel trends in high-throughput screening. , 2009, Current opinion in pharmacology.

[27]  P. Chanda,et al.  A fluorescence-based assay for monoacylglycerol lipase compatible with inhibitor screening. , 2008, Assay and drug development technologies.

[28]  John P. Overington,et al.  Probing the links between in vitro potency, ADMET and physicochemical parameters , 2011, Nature Reviews Drug Discovery.

[29]  Julian Blagg,et al.  Structure–Activity Relationships for In vitro and In vivo Toxicity , 2006 .

[30]  Jens Loesel,et al.  Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file , 2013, Molecular Diversity.

[31]  Roman Boutellier,et al.  Design principles for innovative workspaces to increase efficiency in pharmaceutical R&D: lessons learned from the Novartis campus. , 2013, Drug discovery today.

[32]  Hualin Xi,et al.  The design, annotation, and application of a kinase-targeted library. , 2011, Methods in molecular biology.

[33]  Ricardo Macarron,et al.  Enhancements of screening collections to address areas of unmet medical need: an industry perspective. , 2010, Current opinion in chemical biology.

[34]  Tarek A. Leil,et al.  Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development , 2014, Front. Pharmacol..

[35]  K. M. Smith,et al.  Novel software tools for chemical diversity , 1998 .

[36]  Tian Zhu,et al.  Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. , 2013, Journal of medicinal chemistry.

[37]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[38]  Andreas Bender,et al.  “Plate Cherry Picking”: A Novel Semi-Sequential Screening Paradigm for Cheaper, Faster, Information-Rich Compound Selection , 2007, Journal of biomolecular screening.

[39]  W. Janzen,et al.  Screening technologies for small molecule discovery: the state of the art. , 2014, Chemistry & biology.

[40]  M. Breyer.  Improving productivity of modern-day drug discovery , 2014, Expert opinion on drug discovery.

[41]  Diane Joseph-McCarthy,et al.  Fragment-Based Lead Discovery and Design , 2014, J. Chem. Inf. Model..

[42]  Asher Mullard.  2014 FDA drug approvals , 2015, Nature Reviews Drug Discovery.

[43]  F. Pullen,et al.  The application of non-combinatorial chemistry to lead discovery. , 2001, Drug discovery today.

[44]  S. Rees,et al.  Principles of early drug discovery , 2011, British journal of pharmacology.

[45]  Bert L. de Groot,et al.  Conformational Transitions upon Ligand Binding: Holo-Structure Prediction from Apo Conformations , 2010, PLoS Comput. Biol..

[46]  John L. LaMattina,et al.  The impact of mergers on pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[47]  F. Sams-Dodd,et al.  Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. , 2013, Drug discovery today.

[48]  R. Slusser,et al.  The Paradox of Scientific Excellence and the Search for Productivity in Pharmaceutical Research and Development , 2014, Clinical pharmacology and therapeutics.

[49]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[50]  Jordi Mestres,et al.  Coverage and bias in chemical library design. , 2008, Current opinion in chemical biology.

[51]  Nigel Greene,et al.  Physicochemical drug properties associated with in vivo toxicological outcomes: a review , 2009, Expert opinion on drug metabolism & toxicology.

[52]  Gregory A. Bakken,et al.  A Heuristic Algorithm for Plate SelectionThat Maximizes Compound Diversity , 2013 .